Genetic blood disorders: Questions you need to ask

,

Applied Evidence

Genetic blood disorders: Questions you need to ask

J Fam Pract. 2012 January;61(1):30-37

PDF Download

References

1. Centers for Disease Control and Prevention. Sickle dell disease. Available at: http://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed. Accessed July 5, 2011.

2. Brousseau DC, Panepinto JA, Nimmer M, et al. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2009;85:77-78.

3. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180:326-328.

4. National Heart, Lung, and Blood Institute. What is sickle cell anemia? Available at: http://www.nhlbi.nih.gov/health/health-topics/topics/sca/. Accessed December 14, 2011.

5. National Center for Biotechnology Information. Sickle cell disease. Gene Reviews. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1377/. Accessed December 14, 2011.

6. Serjeant GR. One hundred years of sickle cell disease. Br J Haematol. 2010;151:425-429.

7. National Heart, Lung, and Blood Institute. What are the signs and symptoms of sickle cell disease. Available at: http://www.nhlbi.nih.gov/health/health-topics/topics/sca/signs.html. Accessed December 14, 2011.

8. Candrilli SD, O’Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86:273-277.

9. Hoffer LJ. Folate supplementation in sickle cell anemia. N Engl J Med. 2003;349:813.-

10. ClinicalTrials.gov. Evaluating the safety and effectiveness of bone marrow transplants in children with sickle cell disease (BMT CTN #0601) (The SCURT study). Available at: http://clinicaltrials.gov/ct2/show/NCT00745420?term=sickle+cell+bone+marrow+transplant&rank=1. Accessed December 15, 2011.

11. McKerrell TD, Cohen HW, Billett HH. The older sickle cell patient. Am J Hematol. 2004;76:101-106.

12. Cooley TB, Lee P. Series of cases of splenomegaly in children with anemia and peculiar bon changes. Trans Am Pediatr Soc. 1925;37:29.-

13. Thalassemia. Stedman’s Medical Dictionary. 24th ed. Baltimore, Md: Williams & Wilkins; 1982:1435.

14. Johnson CS, Tegos C, Beutler E. Alpha thalassemia; prevalence and hematologic findings in American blacks. Arch Intern Med. 1982;142:1280-1282.

15. Al-Awamy BH. Thalassemia syndromes in Saudi Arabia; meta-analysis of local studies. Saudi Med J. 2000;21:8-17.

16. Lie-Injo L. Alpha-chain thalassemia and hydrops fetalis in Malaya: report of five cases. Blood. 1962;20:581-590.

17. Chouliaris G, Berdoukas V, Ladis V, et al. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. J Magn Reson Imaging. 2011;34:56-59.

18. Mendilcioglu I, Yakut S, Keser I, et al. Prenatal diagnosis of beta-thalassemia and other hemoglobinopathies in southwestern Turkey. Hemoglobin. 2011;35:47-55.

19. Vichinsky EP. Changing patterns of thalassemia worldwide. Ann NY Acad Sci. 2005;1054:18-24.

20. Cao A, Moi P, Galanello R. Recent advances in beta-thalassemias. Pediatr Rep. 2011;3:e17.-

21. Texas Department of State Health Services. Sickle cell + thalassemia. Available at: http://www.dshs.state.tx.us/newborn/thala.shtm. Accessed December 14, 2011.

22. Weatherall DJ. History of genetic disease: thalassaemia: the long road from bedside to genome. Nat Rev Genet. 2004;5:625-631.

23. Jaffe EK, Stith L. ALAD porphyria is a conformational disease. Am J Hum Genet. 2007;80:329-337.

24. Thunell S, Floderus Y, Henrichson A, et al. Porphyria in Sweden. Physiol Res. 2006;55(suppl 2):S109-S118.

25. James WD, Berger T, Elston D. Andrews’ Diseases of the Skin: Clinical Dermatology. 10th ed. Philadelphia, Pa: Saunders; 2006.

26. Gross U, Hoffman GF, Doss MO. Erythropoietic and hepatic porphyries. J Inherit Metab Dis. 2000;23:641-661.

27. American Porphyria Foundation. About porphyria. Available at: http://www.porphyriafoundation.com/about_porphyria. Accessed December 19, 2011.

28. Boffey PM. Rare disease proposed as cause for “vampires.” New York Times. May 31, 1985. Available at: http://www.nytimes.com/1985/05/31/us/rare-disease-proposed-as-cause-for-vampires.html. Accessed December 15, 2011.

29. Khachemoune A, Blyumin M. Red urine and photosensitive skin rash. J Fam Pract. 2009;58:200-202.

30. Lin CS, Lee NJ, Park SB, et al. Purple pigments: the pathophysiology of acute porphyric neuropathy. Clin Neurophysiol. 2011;122:2336-2344.

31. Seubert S, Seubert A, Stella AM, et al. Results of treatment of porphyria cutanea tarda with bloodletting and chloroquine. Z Hautkr. 1990;65:223-225.

32. Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. 2006;135:281-292.

33. Cainelli T, Di Padova C, Marchesi L, et al. Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda. Br J Dermatol. 1983;108:593-600.

34. McKusick-Nathans Institute of Genetic Medicine. Mendelian Inheritance in Man: A Catalog of Human Genes and Genetic Disorders. Vol .3. Baltimore, Md: Johns Hopkins University; 1998:2305.

35. National Digestive Diseases National Clearinghouse. Hemochromatosis. Available at: http://digestive.niddk.nih.gov/diseases/pubs/hemochromatosis. Accessed December 14, 2011.

36. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139:393-408.

37. American Diabetes Association. Hemochromatosis. Available at: http://www.diabetes.org/living-with-diabetes/complications/related-conditions/hemochromatosis.html. Accessed December 15, 2011.

38. Rocchi E, Gibertini P, Cassanelli M, et al. Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion. Br J Dermatol. 1986;114:621-629.

39. American Hemochromatosis Society. Approved blood banks. Available at: http://www.americanhs.org/approvedbanks.htm. Accessed December 14, 2011.

40. Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010;116:317-325.